AdobeStock_513446727

External Control Arms

Build smarter control groups with fit-for-purpose real-world patient cohorts.

Shorter timelines. Stronger evidence.

Based on a proven methodology built upon 30+ years of experience, TriNetX external control arms (ECAs) help you with timely, representative, granular, and fit-for-purpose control groups.

Designed for studies where randomized controls are impractical, our experts will guide you through set-up, regulations, and execution as we use real-world patient data in lieu of additional patient recruitment, reducing costs and timelines while generating robust, regulation-ready evidence to support your trial.

Lady working at computer looking at data

Navigate regulatory uncertainty with confidence

Strengthen your HTA and EMA submissions with representative, fit-for-purpose ECAs designed for regulatory readiness.

Our methodology ensures scientifically sound data and processes, delivering evidence that regulators can trust and increasing your chances of a successful submission.

Overcome data and implementation challenges

TriNetX ECAs maintain the integrity of your analyses and results while helping you gain deeper insights into treatment impact. You can even generate supplementary control information for prospective experimental arms.

Lady presenting in an office

Want to learn more?

Explore our insights

Terminal Ileum Resection and Colorectal Cancer Risk in Crohn’s Disease: What 19 Years of Real-World Data Show
Blogs

This independently conducted Brief Report, conducted utilizing the TriNetX LIVE™ platform, makes that case in terms that Health Economics and Outcomes Research teams need to confront directly with additional research and contextualization.

Deriving Breast Cancer Stage from Electronic Health Records: A Comparison of Gradient Boosting and Large Language Models Without Task-Specific Training
Poster Presentations

This study compares the performance of a classic ML model and a LLM in deriving breast cancer stage from structured EHR data.

Real-time estimation of the prevalence of exposures during pregnancy to novel therapeutics approved from 2021 to 2024
Poster Presentations

Electronic health record RWD sources may be a more viable approach to monitoring
medication use during pregnancy. We estimate exposure to novel therapeutics during pregnancy in a large EHR research network.

Conception of a framework to assess the capability of real-world data to respond to infectious disease research objectives
Poster Presentations

Infectious disease research spanning stakeholders and purposes can benefit from the inclusion of real-world data (RWD). The fit for RWD in
studying specific ID research components is not well-established beyond study-specific assessment.

Abstract Ocean Water Texture

Contact TriNetX

Need to reach out? We’re here to help.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
TriNetX Marketing Opt In
By subscribing to promotional updates, you agree to the TriNetX Privacy Policy and receiving relevant TriNetX marketing and other promotional emails, from which you can opt out at any time.
TriNetX Privacy Policy*
By submitting this form, you agree to receiving marketing and other promotional emails from us. For opt-out information, as well as TriNetX privacy practices and commitment to protecting your privacy, please review the TriNetX Privacy Policy.
This field is hidden when viewing the form
From Gravity Form

Meet